The drugmakers competing for a $5.6 trillion global medicine market are now being researched inside the chatbox. New 5W research ranks the 25 pharmaceutical companies by how often the AI engines name them.
Source: 5W analysis of AI-generated responses across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, Q2 2026. Share represents the estimated proportion of company citations across 60+ tracked patient and consumer prompts spanning metabolic, oncology, immunology, vaccine, and specialty categories. Remaining ~27.5% split across ranks 16–25 and unranked companies.
Pharma is a $5.6 trillion global industry, and by conventional measures its leaders are Merck — maker of Keytruda, the best-selling drug in the world — alongside Pfizer, Johnson & Johnson, and AbbVie. Those are the companies at the top of the revenue tables.
They are not the companies at the top of the AI answer. The 5W AI Visibility Index finds that Eli Lilly and Novo Nordisk lead the consumer-citation surface — because their drugs are the ones patients actually research. Ozempic, Wegovy, Mounjaro, and Zepbound generated roughly $70 billion in combined 2025 sales and, more importantly, became household names. When a consumer asks ChatGPT or Google's AI Overviews about weight loss, diabetes, or "Ozempic vs Wegovy," the company names that surface are Lilly and Novo.
Keytruda outsells every drug on earth, but oncology medicines are prescribed, not shopped — patients do not type Keytruda into a chatbot the way they type Ozempic. That is the decoupling: consumer AI citation share is driven by the drugs people self-research, not the drugs that earn the most. In a category where patients increasingly research their prescriptions before they research their doctor, the company AI names is the company shaping the conversation.
"Merck makes the best-selling drug in the world. Most patients have never typed its name into a chatbot. Eli Lilly and Novo Nordisk built something more valuable than the top seller — they built the drugs people actually ask AI about. Ozempic and Mounjaro turned two companies into household names inside the answer engines, and the pharma giants ranked by revenue are not the ones ranked by citation. In a category where patients now research their prescriptions before they research their doctor, the company AI names is the company that shapes the conversation."
5W analyzed more than 60 common patient and consumer prompts across six primary sub-categories of the pharmaceutical market, running each prompt five times per engine in clean sessions. We identified which companies AI models consistently surface, which sources feed those citations, and where the biggest gaps sit between revenue and AI visibility.
Eli Lilly, Novo Nordisk, and the diabetes/obesity drug makers.
Merck, AstraZeneca, Bristol Myers Squibb, Roche, Pfizer oncology.
AbbVie, Sanofi, Amgen, and the autoimmune-drug makers.
Pfizer, Moderna, GSK, Gilead Sciences.
Novartis, Bristol Myers Squibb, Bayer, specialty makers.
Teva, Viatris, Organon, and biosimilar producers.
Query types tracked. Real-world prompts including "which company makes Ozempic," "Ozempic vs Wegovy vs Mounjaro," "largest pharmaceutical companies," "who makes the COVID vaccine," "best company for diabetes drugs," "what company makes Humira," and 50+ variations covering company-identification, comparison, and category-leadership intent. Prompts were framed at the company and category level, not as treatment-selection queries.
Citation sources tracked. Business and health editorial (Reuters, Bloomberg, Fierce Pharma, STAT, Pharm Exec), reference sources (company filings, Wikipedia, Drugs.com), news coverage, and brand-owned corporate content.
| # | Company | Category | AI Visibility | Notable |
|---|---|---|---|---|
| 1 | Eli Lilly | Metabolic / GLP-1 | Category-dominant | NYSE: LLY; Mounjaro and Zepbound; targeting ~$80B 2026 revenue; briefly the first healthcare company past a $1T market cap. |
| 2 | Novo Nordisk | Metabolic / GLP-1 | Citation co-leader | NYSE: NVO; Ozempic and Wegovy; owns "weight loss drug" citations; holds the majority of the GLP-1 market. |
| 3 | Pfizer | Diversified / vaccines | Consumer-recognition tier | NYSE: PFE; ~$63B 2024 revenue; COVID-era vaccine and Paxlovid recognition keeps it high in consumer citations. |
| 4 | Johnson & Johnson | Diversified | Diversified-giant tier | NYSE: JNJ; Innovative Medicine plus MedTech; broad name recognition even after the Kenvue consumer-health spin-off. |
| 5 | Merck | Oncology | Revenue leader, #5 by citation | NYSE: MRK; Keytruda is the world's best-selling drug — but oncology is prescribed, not shopped, so consumer citations trail revenue. |
| 6 | AbbVie | Immunology & inflammation | DTC-driven tier | NYSE: ABBV; Humira, Skyrizi, Rinvoq; heavy direct-to-consumer advertising lifts its citation share. |
| 7 | AstraZeneca | Oncology & specialty | Specialty tier | NASDAQ: AZN; fast-growing oncology and cardiometabolic portfolio; strong but specialist-led citation profile. |
| 8 | Moderna | Vaccines & mRNA | Pandemic-recognition tier | NASDAQ: MRNA; COVID-era name recognition keeps it cited in vaccine and mRNA queries above its revenue rank. |
| 9 | Amgen | Biologics & specialty | Biologics tier | NASDAQ: AMGN; large biologics portfolio and a GLP-1 candidate in development; specialist-led citations. |
| 10 | Novartis | Specialty & gene therapy | Specialty tier | NYSE: NVS; cell, gene, and specialty therapies; thinner consumer citation share. |
| 11 | Bristol Myers Squibb | Oncology & cardiovascular | Specialty tier | NYSE: BMY; Eliquis and an oncology franchise; cited mainly in condition-specific queries. |
| 12 | GSK | Vaccines & respiratory | Vaccine-maker tier | NYSE: GSK; strong vaccine and respiratory portfolio; cited heavily in vaccine queries. |
| 13 | Sanofi | Immunology & vaccines | Immunology tier | NASDAQ: SNY; Dupixent (with Regeneron) anchors its citations; broad but specialist-led profile. |
| 14 | Gilead Sciences | Antivirals & oncology | Antiviral tier | NASDAQ: GILD; HIV and antiviral leadership; Biktarvy anchors its citation share. |
| 15 | Roche | Oncology & diagnostics | Diagnostics-led tier | Swiss group; oncology and diagnostics leader; lower U.S. consumer citation share despite scale. |
| 16 | Bayer | Diversified | Diversified niche | Pharma plus consumer health and crop science; pharma citation share diluted by the conglomerate structure. |
| 17 | Regeneron | Immunology & specialty | Specialty niche | NASDAQ: REGN; Dupixent and Eylea; cited in condition-specific queries. |
| 18 | Vertex Pharmaceuticals | Rare disease | Rare-disease niche | NASDAQ: VRTX; cystic fibrosis leadership; narrow but uncontested citation niche. |
| 19 | Boehringer Ingelheim | Diversified / private | Private-company niche | Privately held; Jardiance partnership with Lilly; lower citation visibility as a private company. |
| 20 | Teva | Generics & biosimilars | Generics tier | NYSE: TEVA; the largest generic-drug maker; cited in generics and affordability queries. |
| 21 | Biogen | Neuroscience | Neuroscience niche | NASDAQ: BIIB; neuroscience and Alzheimer's focus; cited in condition-specific queries. |
| 22 | Takeda | Diversified / specialty | Specialty niche | NYSE: TAK; Japanese group; rare disease and gastroenterology; modest U.S. consumer citation share. |
| 23 | Viatris | Generics & biosimilars | Generics niche | NASDAQ: VTRS; generics and biosimilars; cited mainly in affordability and access queries. |
| 24 | CSL | Plasma & vaccines | Plasma niche | Australian group; plasma therapies and vaccines; narrow specialist citation footprint. |
| 25 | Organon | Women's health | Women's-health niche | NYSE: OGN; women's health spin-off from Merck; small but defined citation niche. |
Mounjaro and Zepbound did more than drive revenue — they made Eli Lilly a household name inside the answer engines. When consumers research weight loss or diabetes, Lilly is the company AI surfaces, and that consumer-citation lead has no equal in the category.
Ozempic became one of the most-searched drug names in the world, and Wegovy extended it into obesity. That recognition pulls Novo Nordisk's corporate name into a huge share of consumer health queries — visibility a traditional campaign could never buy.
The COVID-19 vaccine made Pfizer one of the most recognized company names on earth. That recognition still compounds: Pfizer ranks third in citations, well above where its current revenue mix alone would place it.
AbbVie's heavy direct-to-consumer advertising for Humira, Skyrizi, and Rinvoq put its drug names into wide public circulation — and that circulation feeds editorial coverage and citations the engines retrieve.
Merck makes the best-selling drug in the world, yet ranks fifth in citations. Oncology medicines are prescribed by specialists, not researched by patients shopping — so the consumer-citation surface badly trails oncology revenue.
Bayer and other conglomerates split their identity across pharma, consumer health, and unrelated businesses. That diffuse structure dilutes pharmaceutical citation share — the engines cannot attribute a clear category position.
Private companies generate less of the filings, investor coverage, and news flow that feed AI citations. Capable private drugmakers underindex relative to their actual scale.
Teva and Viatris are major manufacturers, but they surface mainly in affordability and access queries. AI answers about specific conditions route to branded innovators, leaving generics in a narrow citation lane.
The highest-earning companies are not the most-cited. Consumer citation follows the drugs patients research, not the income statement.
Ozempic and Mounjaro made Novo and Lilly household names. The drug brand is the company's most powerful citation asset.
Weight, diabetes, and immunology — conditions patients actively research — generate citations. Specialist-prescribed categories generate far fewer.
DTC puts drug names into public circulation, which feeds the editorial coverage AI engines retrieve. The effect outlasts the ad spend.
Conglomerates and private companies underindex. A clear, public, single-category identity earns the answer.
A growing share of patients arrive at the doctor having already read an AI answer. Corporate citation share is now upstream of the prescription conversation.
Combined GLP-1 sales near $70B and the news flow around them keep Lilly and Novo at the top of the consumer-citation surface.
As GLP-1 therapies move toward pills, a wave of coverage is likely to reshape metabolic-category citations again.
Looming losses of exclusivity on major drugs are shifting how AI answers describe the pipelines of affected companies.
Drug-pricing debate generates heavy news flow — and AI answers increasingly surface pricing context in company queries.
Trials in sleep apnea, heart, and cognitive health are extending the metabolic leaders' citation surface into new conditions.
Companies positioning around AI in R&D are beginning to earn citations in a query category that did not exist a year ago.
For decades, pharmaceutical brand awareness was shaped by detailing to physicians and direct-to-consumer advertising. Today a growing share of patients arrive at the doctor's office having already asked ChatGPT, Claude, or Google's AI Overviews about their condition and their options. The citation surface has become upstream of the prescription itself.
The Index shows what that surface rewards: the drugs patients self-research, the company names a blockbuster drags into public consciousness, a clear category identity, and a deep, accurate editorial and reference record. It does not simply track revenue — Merck's best-in-world drug does not make Merck the best-cited company.
AI citation share is the scoreboard. In pharma, the company AI names is the company shaping how patients understand their options — and that visibility is built in the public record, not the revenue table.